⚠️ Important Notice This article is for general education only and is not personal medical advice. Medication names, doses, and tests mentioned are general information — your own doctor will decide what is right for you based on your individual health. Never start, stop, or change any diabetes medicine without talking to your doctor first.
Before publishing: Please have a HealthNep partner doctor review this article for medical accuracy before it goes live on the platform.
What is Diabetes?
Types of Diabetes and Their Root Causes
Complications from Diabetes
Treatment Plans
Role of Exercise and Best Exercises
Types of Medication and Starting Points
Side Effects — Minor and Major
Tests Before Starting Each Medication
Tests After Starting Each Medication
Ayurvedic Approach
Keto vs. Balanced Diet
Myths vs. Facts
Recent Research and New Drugs
References
Diabetes is a long-term condition in which the body cannot properly regulate the amount of glucose (sugar) in the blood. This happens either because the pancreas does not make enough insulin, the body cannot use the insulin it makes, or both. Insulin is the hormone that allows glucose from food to move out of the blood and into the body's cells, where it is used for energy. When insulin does not work properly, glucose builds up in the blood, and over many years this high blood sugar can quietly damage blood vessels, nerves, and organs throughout the body — even before a person feels sick.
There are several distinct types of diabetes, and each has a different underlying cause.
Type 1 diabetes is an autoimmune condition. The body's own immune system mistakenly attacks and destroys the insulin-producing beta cells inside the pancreas, usually driven by a mix of genetic risk (certain HLA gene patterns) and an unknown environmental trigger, possibly a viral infection. Because the beta cells are destroyed, the body ends up with little or no insulin of its own, and lifelong insulin treatment becomes necessary from diagnosis onward. Diet or lifestyle does not cause type 1 diabetes.
Type 2 diabetes — the most common form — develops from a combination of insulin resistance (the body's cells stop responding well to insulin) and a gradual decline in the pancreas's ability to produce enough insulin to keep up with demand. Genetics, excess body weight (especially abdominal fat), physical inactivity, aging, and poor diet all contribute together over time; it is rarely caused by a single factor alone.
Gestational diabetes occurs during pregnancy, usually in the second or third trimester. Hormones produced by the placenta interfere with how the mother's body uses insulin, and in some women the pancreas cannot produce enough extra insulin to compensate, so blood sugar rises.
Other specific types, such as monogenic diabetes (MODY), result from a mutation in a single gene affecting how beta cells work, and are inherited within families.
Chronically high blood sugar damages blood vessels throughout the body, and the resulting complications are generally grouped into two categories. Microvascular complications affect small blood vessels and include diabetic retinopathy (progressive damage to the retina that can lead to blindness), diabetic nephropathy (kidney damage that can progress to kidney failure), and diabetic neuropathy (nerve damage causing numbness, tingling, or pain, most often in the feet). Macrovascular complications affect larger blood vessels and include a substantially increased risk of heart attack, stroke, and peripheral artery disease. Research following people with diabetes over ten years found that those with microvascular complications had a clearly higher risk of major cardiovascular events and death compared to those without, and the risk climbed further with each additional complication present. This is precisely why regular eye exams, kidney function tests, and foot checks are recommended for every person with diabetes, even when they feel completely well.
The American Diabetes Association's Standards of Care describes diabetes treatment as an individualized, ongoing process rather than a single fixed plan. A typical treatment plan brings together several elements working together: blood sugar monitoring (through home glucose checks and regular HbA1c blood tests every 3 months), medical nutrition therapy tailored to the person's preferences and culture, structured physical activity, medication when lifestyle changes alone are not enough, and regular screening for complications (eyes, kidneys, feet, heart). Treatment targets are personalized — a target that is appropriate for a healthy 40-year-old may not be appropriate for a frail 80-year-old — and the plan is expected to be reviewed and adjusted at every visit as the person's health, other conditions, and life circumstances change over time.
Exercise is considered a cornerstone of diabetes management alongside diet and medication. Physical activity helps muscles pull glucose out of the bloodstream both during and after the activity, and regular exercise also improves how sensitive the body's cells are to insulin, meaning the insulin the body has works better. A 2025 review of 26 studies found that moderate-to-vigorous aerobic exercise (such as brisk walking, cycling, or swimming) improved insulin sensitivity and HbA1c, resistance training (such as weightlifting or resistance bands) improved glycemic markers with somewhat inconsistent effects on insulin resistance itself, and combined aerobic-plus-resistance programs tended to produce the best overall results across fasting glucose, HbA1c, and insulin sensitivity together. A newer laboratory study from Virginia Tech (2025) further suggested resistance-type training may outperform pure endurance exercise for improving insulin sensitivity in obesity and type 2 diabetes models specifically. In practice, most guidelines recommend at least 150 minutes per week of moderate aerobic activity combined with resistance exercises on two or more days per week, with short walks after meals also shown to blunt the after-meal blood sugar spike.
Diabetes medications work through several different mechanisms, and doctors typically start with one class and add others as needed. The following are general starting approaches — your doctor personalizes the actual dose for you.
Medication Class
Examples
How It Works
General Starting Approach
Biguanide
Metformin
Reduces glucose made by the liver, improves insulin sensitivity
Usually first-line; started at a low dose with food and increased gradually over several weeks
Sulfonylureas
Glimepiride, Glipizide, Glyburide
Stimulates the pancreas to release more insulin
Started at the lowest dose, taken before meals, adjusted slowly
DPP-4 Inhibitors
Sitagliptin, Linagliptin
Raises natural incretin hormones that help insulin release after meals
Usually a single fixed daily dose
SGLT2 Inhibitors
Empagliflozin, Dapagliflozin, Canagliflozin
Causes the kidneys to remove excess glucose through urine
Started at the lowest approved dose once daily in the morning
GLP-1 Receptor Agonists
Liraglutide, Semaglutide, Dulaglutide
Mimics gut hormones, slows digestion, reduces appetite, boosts insulin release
Started at a very low dose and increased slowly over weeks to reduce nausea
Thiazolidinediones
Pioglitazone
Improves how muscle and fat cells respond to insulin
Started at a low dose, effects build up over weeks
Insulin
Basal (long-acting), Bolus (rapid-acting), Premixed
Directly replaces or supplements the body's own insulin
Dose is calculated individually based on weight, blood sugar patterns, and diet
Medication Class
Minor / Common Side Effects
Major / Serious Side Effects
Metformin
Nausea, diarrhea, stomach upset (usually improves with time)
Lactic acidosis (very rare, mostly in kidney impairment); vitamin B12 deficiency with long-term use
Sulfonylureas
Mild low blood sugar, slight weight gain
Severe hypoglycemia, especially in elderly patients or those with reduced kidney function
DPP-4 Inhibitors
Headache, mild cold-like symptoms, joint discomfort
Rare pancreatitis; rare severe joint pain
SGLT2 Inhibitors
Genital yeast infections, urinary tract infections, increased urination
Dehydration, low blood pressure, rare diabetic ketoacidosis even with near-normal blood sugar, rare Fournier's gangrene
GLP-1 Receptor Agonists
Nausea and vomiting, especially when starting or increasing dose
Rare pancreatitis, gallbladder problems; not used in those with a personal/family history of certain thyroid cancers
Thiazolidinediones
Weight gain, fluid retention/swelling
Can worsen heart failure; increased bone fracture risk
Insulin
Weight gain, injection site reactions
Hypoglycemia (can be severe if dose is too high or a meal is skipped)
Before Starting
Recommended Tests
Metformin
Kidney function (eGFR/creatinine) — this medicine is avoided or dose-reduced with significant kidney impairment
Sulfonylureas
Kidney and liver function; baseline blood sugar pattern to gauge hypoglycemia risk
DPP-4 Inhibitors
Kidney function (some need dose adjustment)
SGLT2 Inhibitors
Kidney function (eGFR); volume/hydration status; history of recurrent genital infections
GLP-1 Receptor Agonists
Personal/family history of medullary thyroid cancer or MEN2 syndrome; history of pancreatitis or gallbladder disease
Thiazolidinediones
Liver function tests; heart failure history/assessment
Insulin
Fasting C-peptide and diabetes autoantibodies (GAD, IA-2, ZnT8, insulin antibodies) — especially important when it is unclear whether someone has type 1 or type 2 diabetes, since this changes the whole treatment approach; also kidney and liver function
After Starting
Recommended Follow-Up Tests
Metformin
Annual kidney function check; annual vitamin B12 level with long-term use
Sulfonylureas
Regular blood glucose self-monitoring to detect hypoglycemia
DPP-4 Inhibitors
Periodic kidney function; watch for joint or abdominal pain
SGLT2 Inhibitors
Periodic kidney function; watch for signs of infection or dehydration, especially during illness
GLP-1 Receptor Agonists
Watch for persistent abdominal pain (pancreatitis warning sign); weight and appetite tracking
Thiazolidinediones
Liver function checks; watch for swelling/shortness of breath
Insulin
Regular self-monitored blood glucose, HbA1c every 3 months, and hypoglycemia awareness education. (Note: once someone is on injected insulin, insulin blood tests become unreliable for judging their own production, so HbA1c and glucose monitoring — not repeat C-peptide — become the main ongoing tools)
Several herbs commonly used in Ayurvedic medicine have been studied for their effect on blood sugar. A comprehensive systematic review commissioned by the U.S. Agency for Healthcare Research and Quality examined 54 published studies and found preliminary evidence that certain single herbs — including Gymnema sylvestre, Coccinia indica, fenugreek (Trigonella foenum-graecum), and holy basil — along with the compound formulas Ayush-82 and D-400, showed a glucose-lowering effect worth further study, though the overall evidence base was described as inconsistent in quality and in need of larger, better-designed trials. More recent smaller trials have reported specific findings, such as one placebo-controlled study showing a reduction in HbA1c over 16 weeks with Gymnema sylvestre extract, and a meta-analysis finding fenugreek improved fasting glucose and insulin sensitivity in the majority of trials reviewed. It is important to understand that these herbs are studied mainly as add-on or complementary approaches, not replacements for prescribed medication, and they can interact with diabetes drugs to cause unexpectedly low blood sugar — anyone wanting to use them should tell their doctor first, especially before combining them with insulin or sulfonylureas.
Ketogenic diet: This very-low-carbohydrate, high-fat eating pattern forces the body to burn fat for fuel instead of glucose. Some clinical studies show meaningful short- and medium-term benefits — one systematic review of low-carbohydrate and ketogenic diets followed for one to eight years found diabetes remission rates as high as 62% at one year, though this fell to around 13% by year five as many participants regained weight and glycemic control. A retrospective study also found a very-low-calorie ketogenic diet reduced HbA1c more than a standard low-calorie diet, and allowed some participants to stop diabetes medication entirely.
Pros: Rapid blood sugar and weight improvement; can reduce medication needs.
Cons: Very hard to sustain long-term; cuts out fiber-rich fruits, legumes, and whole grains unless carefully planned; long-term safety data beyond a few years is lacking; people on SGLT2 inhibitors are specifically warned to avoid very-low-carb/keto diets due to a raised risk of diabetic ketoacidosis; the American Diabetes Association does not recommend one universal diet over another.
Balanced diet with fiber: This approach includes a moderate mix of carbohydrates (favoring whole grains, legumes, vegetables), lean protein, healthy fats, and generous fiber. A World Health Organization–supported series of reviews found that people eating the most dietary fiber had 15–30% lower rates of all-cause mortality, cardiovascular disease, and new type 2 diabetes compared to those eating the least, along with lower body weight and blood pressure.
Pros: Sustainable long-term; supported by strong population-level evidence for heart and diabetes protection; easier to personalize to Nepali food habits (dal, vegetables, whole grains in modest portions).
Cons: Slower initial results than keto; still requires portion awareness and consistency; not risk-free if "balanced" is misunderstood as unlimited rice or refined carbohydrates.
Bottom line: Neither approach is "one-size-fits-all." Keto may suit short, medically supervised periods for some people with type 2 diabetes; a fiber-rich balanced diet is generally easier to sustain for life and has stronger long-term population evidence. This decision should always be made with a doctor or dietitian, particularly for anyone on insulin or SGLT2 inhibitors.
Myth
Fact
Eating too much sugar directly causes diabetes
Excess sugar and sugary drinks contribute to weight gain, which raises type 2 diabetes risk, but sugar alone does not directly cause diabetes — diabetes results from a mix of genetics, weight, and lifestyle factors
People with diabetes can never eat fruit
Whole fruits contain fiber that slows sugar absorption and provide important vitamins; portion control matters more than complete avoidance
Type 1 diabetes turns into Type 2 as you get older
Type 1 remains an autoimmune condition for life and does not convert into Type 2 with age
If no one in the family has diabetes, you won't get it
Family history raises risk but most people who develop type 2 diabetes have no close relative with it — lifestyle and weight matter greatly too
Type 2 diabetes is "less serious" than Type 1
Both types carry serious long-term complication risks if blood sugar is not controlled; type 2 is more common but not inherently milder
Insulin means your diabetes has become dangerous or you failed
Type 2 diabetes is progressive by nature — the pancreas naturally makes less insulin over time for many people, and starting insulin is a normal, expected part of treatment for some, not a punishment or failure
Only overweight people get diabetes
Type 1 diabetes is unrelated to weight, and even some people with type 2 diabetes are of normal weight
Diabetes drug research has moved rapidly in the past two years, especially in the GLP-1 hormone-based medication family. Key recent developments include:
Orforglipron, the first oral, small-molecule (non-injectable, non-peptide) GLP-1 medication, received FDA approval in April 2026 for weight management and has shown A1C reductions of 1.8–2.2% along with meaningful weight loss in clinical trials — its main advantage is that, unlike earlier oral peptide drugs, it can be taken at any time without food or water restrictions.
Retatrutide, a "triple agonist" drug that activates three different gut hormone receptors (GLP-1, GIP, and glucagon) at once, met its main goals in a late-stage (Phase 3) trial in people with type 2 diabetes published in March 2026: it lowered HbA1c by an average of 1.7–2.0% and helped patients lose up to 16.8% of their body weight over 40 weeks. It is still investigational and not yet approved for general use.
Oral semaglutide (a pill form of an already-approved injectable GLP-1 drug) launched for weight management in January 2026, alongside continued approval expansions for injectable semaglutide and tirzepatide into other conditions such as chronic kidney disease and sleep apnea.
Across this new generation of drugs, researchers describe a clear trend: each additional hormone receptor targeted by a new drug tends to produce greater blood sugar and weight improvements, though this often comes with more gastrointestinal side effects during the initial dose build-up period.
These are genuinely exciting developments, but nearly all of them are new, some are not yet approved everywhere, and none replace the basic, well-proven pillars of diabetes care — diet, exercise, and consistent use of established medications under a doctor's supervision.
Healthline — Type 1 vs. Type 2 Diabetes Differences (medically reviewed, updated Jul 2025): https://www.healthline.com/health/difference-between-type-1-and-type-2-diabetes
American Diabetes Association — Standards of Care in Diabetes 2026, Diagnosis & Classification: https://diabetesjournals.org/care/article/49/Supplement_1/S27/163926/2-Diagnosis-and-Classification-of-Diabetes
PMC — Cardiovascular Complications of Diabetes: From Microvascular to Macrovascular Pathways: https://pmc.ncbi.nlm.nih.gov/articles/PMC10594042/
Cardiovascular Diabetology — Microvascular complications and 10-year cardiovascular risk in Type 1 diabetes: https://link.springer.com/article/10.1186/s12933-019-0961-7
American Diabetes Association — Standards of Care 2026, Retinopathy, Neuropathy and Foot Care: https://pmc.ncbi.nlm.nih.gov/articles/PMC12690177/
MDPI — Optimizing Exercise for Type 2 Diabetes Management (2025 review of 26 studies): https://www.mdpi.com/2218-1989/15/11/739
Virginia Tech News — Resistance training vs. endurance exercise for insulin sensitivity (2025/2026): https://news.vt.edu/articles/2025/11/research_fralinbiomed_yanweightlifting.html
PMC — ACSM/ADA Joint Position Statement: Exercise and Type 2 Diabetes: https://pmc.ncbi.nlm.nih.gov/articles/PMC2992225/
American Diabetes Association — Type 2 Diabetes Medication Options: https://diabetes.org/health-wellness/medication/oral-other-injectable-diabetes-medications
Diabetes Canada — Pharmacologic Glycemic Management Guidelines: https://www.diabetes.ca/health-care-providers/clinical-practice-guidelines/chapter-13
Cleveland Clinic — SGLT2 Inhibitors: Uses and Side Effects: https://my.clevelandclinic.org/health/treatments/sglt2-inhibitors
PMC — Diabetic Agents: From Metformin to SGLT2 Inhibitors and GLP-1 Receptor Agonists: https://pmc.ncbi.nlm.nih.gov/articles/PMC7219531/
Mayo Clinic Labs — C-Peptide, Serum Test Overview: https://www.mayocliniclabs.com/test-catalog/overview/8804
SiPhox Health — C-Peptide vs. Insulin Tests Explained: https://siphoxhealth.com/articles/cpeptide-vs-insulin-tests-whats-the-difference
PMC — C-Peptide in Precision Diabetes Care: A Comprehensive Review: https://pmc.ncbi.nlm.nih.gov/articles/PMC12905110/
AHRQ/NCBI Bookshelf — Ayurvedic Interventions for Diabetes Mellitus: A Systematic Review: https://www.ncbi.nlm.nih.gov/books/NBK11924/
PMC — Non-traditional therapies for diabetes: fact or fiction: https://pmc.ncbi.nlm.nih.gov/articles/PMC3714056/
Medical News Today — Ketogenic Diet for Type 2 Diabetes: Risks and Benefits (2025): https://www.medicalnewstoday.com/articles/317431
Cleveland Clinic — Is the Ketogenic Diet Safe for People with Diabetes?: https://health.clevelandclinic.org/is-the-ketogenic-diet-safe-for-people-with-diabetes
PMC — Long-Term Efficacy and Safety of Low-Carbohydrate Diet in Type 2 Diabetes Remission: A Systematic Review: https://pmc.ncbi.nlm.nih.gov/articles/PMC12476234/
PMC — Low-Carb and Ketogenic Diets in Type 1 and Type 2 Diabetes (WHO-supported fiber review): https://pmc.ncbi.nlm.nih.gov/articles/PMC6566854/
MedlinePlus (NIH) — Diabetes Myths and Facts: https://medlineplus.gov/ency/patientinstructions/000964.htm
Tufts Medicine — Busting Diabetes Myths: https://www.tuftsmedicine.org/about-us/news/busting-diabetes-myths
University of Rochester Medicine — Diabetes Myths Debunked: https://www.urmc.rochester.edu/news/publications/health-matters/diabetes-myths
CNBC — Eli Lilly's Retatrutide Clears First Late-Stage Diabetes Trial (March 2026): https://www.cnbc.com/2026/03/19/eli-lillys-obesity-drug-retatrutide-clears-late-stage-diabetes-trial.html
Drug Discovery News — GLP-1 Agonist Clinical Pipeline 2026: https://www.drugdiscoverynews.com/glp-1-agonist-clinical-pipeline-2026-semaglutide-tirzepatide-and-what-s-in-phase-2-17286
PMC — From Needles to Pills: Oral GLP-1 Therapy Enters the Obesity Arena (ATTAIN-1, OASIS-4 trials): https://pmc.ncbi.nlm.nih.gov/articles/PMC12498447/
IQVIA — Outlook for Obesity in 2026 (drug approvals and label expansions): https://www.iqvia.com/locations/emea/blogs/2026/01/outlook-for-obesity-in-2026
Prepared for HealthNep — Nepal's Digital Health Platform. This article should be reviewed by a licensed physician before publishing, and updated periodically as new research becomes available.
This article has been published by the Healthnep editorial team for general information and educational purposes only. The author is not a licensed medical doctor or professional healthcare practitioner. The content provided here does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or a qualified health provider regarding any medical condition or before starting any new treatment. Never disregard professional medical advice or delay seeking it because of something you have read on this platform.
मधुमेह: एक पूर्ण जानकारीHealthNep Patient Educatio...
Read More